Timing of insulin pump initiation among individuals with type 1 diabetes in Ontario, Canada
Zhu X, Lipscombe LL, Shulman R, Lovblom LE, Everett K, Weisman A. Diabetes Obes Metab. 2026; Jan 26 [Epub ahead of print].
Publications
Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA. BMJ Open Diabetes Res Care. 2025; 13(4):e004677.
Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada
Soliman Y, Everett K, Shulman R, Austin PC, Lipscombe L, Booth G, Weisman A. Diabetes Obes Metab. 2025; Jun 24 [Epub ahead of print].
Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART
Thompson W, Wong B, Sivaswamy A, Ferreria-Legere L, Lee DS, Abdel-Qadir H, Ko DT, Weisman A, Tobe S, Jackevicius CA, Goodman SG, Farkouh ME, Udell JA. CJC Open. 2025; Feb 18 [Epub ahead of print].
Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada
Soliman Y, Everett K, Shulman R, Austin PC, Lipscombe LL, Booth GL, Weisman A. Diabetes Obes Metab. 2024; Jul 26 [Epub ahead of print].
Recent improvements in attainment of the hemoglobin A1c target of ≤7.0% among adults with type 1 diabetes in Ontario: a retrospective cohort study
Weisman A, Booth G, Everett K, Tomlinson GA. Diabetes Technol Ther. 2024; Mar 25 [Epub ahead of print].
Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data
Ravaut M, Sadeghi H, Leung KK, Volkovs M, Kornas K, Harish V, Watson T, Lewis GF, Weisman A, Poutanen T, Rosella L. NPJ Digit Med. 2021; 4(1):24. Epub 2021 Feb 12.
Validation of a type 1 diabetes algorithm using electronic medical records and administrative healthcare data to study the population incidence and prevalence of type 1 diabetes in Ontario, Canada
Weisman A, Tu K, Young J, Kumar M, Austin PC, Jaakkimainen L, Lipscombe L, Aronson R, Booth GL. BMJ Open Diabetes Res Care. 2020; 8(1):e001224. Epub 2020 Jun 21.
Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: a retrospective, population-based cohort study
Weisman A, Tomlinson GA, Lipscombe LL, Perkins BA, Hawker GA. Diabetes Obes Metab. 2019; 21(6):1322-9. Epub 2019 Feb 8.